LXH254X
Total Payments
$648,128
Transactions
7
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $648,128 | 7 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $648,128 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I DOSE FINDING STUDY OF ORAL LXH254 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS | Novartis Pharmaceuticals Corporation | $381,294 | 0 |
| A PHASE IB OPEN LABEL MULTICENTER STUDY OF ORAL LXH254 IN COMBINATION WITH ORAL LTT462 IN ADULT PATIENTS WITH ADVANCED OR METASTATIC KRAS OR BRAF MUTANT NON SMALL CELL LUNG CANCER | Novartis Pharmaceuticals Corporation | $266,691 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $143.25 | 1 |
Top Doctors Receiving Payments for LXH254X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $647,985 | 6 |
| , M.D, PHD | Internal Medicine | Houston, TX | $143.25 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $648,128
Product Information
- Type Drug
- Total Payments $648,128
- Total Doctors 1
- Transactions 7
About LXH254X
LXH254X is a drug associated with $648,128 in payments to 1 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $648,128 was paid across 7 transactions to 1 doctors.
The most common payment nature for LXH254X is "Unspecified" ($648,128, 100.0% of total).
LXH254X is associated with 3 research studies, including "A PHASE I DOSE FINDING STUDY OF ORAL LXH254 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS" ($381,294).